Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma.

Oncoimmunology ·Vol. 1 ·No. 4 ·2012-07-01 ·Pages 526-528

Speeckaert R, Van Geel N, Lambert J, Boone B, Chevolet I, Van Gele M, Speeckaert MM, Brochez L

Abstract

Insights into immune reactions against benign and malignant melanocytes may help the development of more efficient immunotherapeutic treatments for melanoma. The interplay between an active systemic antitumor immunity and a responsive local tumor environment is crucial to achieve effective clinical responses. Increasing evidence confirms this strategy can lead to an adequate and durable immunosurveillance of melanocytes.

Authors & Affiliations

8 authors, click to expand affiliations / ORCID

Speeckaert Reinhart

Department of Dermatology; Ghent University Hospital; Gent, Belgium.

Van Geel Nanja

Lambert Jo

Boone Barbara

Chevolet Ines

Van Gele Mireille

Speeckaert Marijn M

Brochez Lieve

References (9)

9 references, click to expand

The haptenation theory of vitiligo and melanoma rejection: a close-up.
Exp Dermatol. 2011 Feb;20(2):92-6 PMID: 21255087
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Eur J Cancer. 2012 Sep;48(13):2004-11 PMID: 22033321
Immunomodulation by imiquimod in patients with high-risk primary melanoma.
J Invest Dermatol. 2012 Jan;132(1):163-9 PMID: 21850019
In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial.
Pigment Cell Melanoma Res. 2012 Jan;25(1):57-65 PMID: 21982055
Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
Anticancer Res. 2011 Nov;31(11):3697-703 PMID: 22110189
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.
Ann Oncol. 2010 Feb;21(2):409-414 PMID: 19622589
The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients.
J Cutan Pathol. 2006 May;33(5):335-42 PMID: 16640539
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.
J Transl Med. 2005 Mar 02;3(1):10 PMID: 15740633
Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity.
Pigment Cell Melanoma Res. 2011 Aug;24(4):673-9 PMID: 21689385

Article Info

Journal

Oncoimmunology

Abbr.

Oncoimmunology

ISSN

2162-4011

DOI

10.4161/onci.19403

Published

2012-07-01

Pages

526-528

Language

English

Region

United States

NLM ID

101570526

PMCID

PMC3382893

External Links

PubMed source DOI: 10.4161/onci.19403 PMC Full Text

Analysis Services

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma.

Contact

WeChat Official Account